Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000, Lille, France.
Eur J Clin Pharmacol. 2021 Sep;77(9):1309-1321. doi: 10.1007/s00228-021-03112-1. Epub 2021 Mar 25.
Drug protocols in intensive care units may require the concomitant administration of many drugs as patients' venous accesses are often limited. A major challenge for clinicians is to limit the risk of simultaneously infusing incompatible drugs. Incompatibilities can lead to the formation of particles and inactivation of drugs, whose consequences on the body have already been indicated. Our objective was to assess current strategies to counter the risk of incompatible infusions and control the resulting clinical consequences.
This review was independently conducted by three investigators in respect of the PRISMA statement. Three online databases were consulted. Full-text articles, notes, or letters written in English or French, published or in press between the 1990s and the end of February 2020, with clinical study design, were eligible. Parameters of interest were mainly number and size of particles, and a number of observed/avoided incompatibilities.
All in all, 382 articles were screened, 17 meeting all the acceptance criteria. The strategies outlined and assessed were filtration, the use of multi-lumen devices, the purging of infusion lines, incompatibility tables and databases, and the use of standard operating procedures.
Although many strategies have been developed in recent years to address drug incompatibility risks, clinical data is still lacking. All studies with in vitro design were excluded although some current innovative strategies, like niosomes, should be considered and studied by means of clinical data in the future.
在重症监护病房中,药物方案可能需要同时使用多种药物,因为患者的静脉通路通常很有限。临床医生面临的主要挑战是限制同时输注不相容药物的风险。不相容性可能导致形成颗粒和药物失活,其对人体的后果已经被指出。我们的目的是评估当前应对不相容输液风险的策略,并控制由此产生的临床后果。
本综述由三位研究者根据 PRISMA 声明独立进行。查阅了三个在线数据库。符合条件的是在 1990 年代至 2020 年 2 月底之间发表或即将发表的具有临床研究设计的英文或法文全文文章、注释或信函。感兴趣的参数主要是颗粒的数量和大小,以及观察到/避免的不相容性数量。
总共筛选了 382 篇文章,其中 17 篇符合所有纳入标准。概述和评估的策略包括过滤、使用多腔设备、冲洗输液管路、不相容性表和数据库以及使用标准操作程序。
尽管近年来已经开发了许多策略来解决药物不相容性风险,但仍缺乏临床数据。所有具有体外设计的研究均被排除在外,尽管一些当前的创新策略,如囊泡,应在未来通过临床数据进行考虑和研究。